[A19-84] Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V

Last updated 02.04.2020

Project no.:

Commission awarded on 27.09.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


First-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR-mutant or ALK-positive NSCLC

Result of dossier assessment:

Added benefit neither proven in PD-L1 expression (TPS) < 50% nor in PD-L1 expression (TPS) > 50%


The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-02.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form